Search results
Results from the WOW.Com Content Network
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]
A recent study found that providing immunotherapy pre- and post-surgery helps improve survival rates compared to only receiving chemotherapy before surgery.
Oncology is one of the fastest-growing segments of drug development and, given the needs of cancer sufferers that aren't met, that's good news. It's also good business. Cancer-fighting drugs did ...
In May 2013, he was diagnosed with stage-4 non-small-cell EGFR-positive lung cancer. [3] As Kalanithi underwent cancer treatment, he shared his reflections on illness and medicine, authoring essays in The New York Times, [4] The Paris Review, [5] and Stanford Medicine, [6] and participating in interviews for media outlets and public forums. [7]
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [159] A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. [160]
Doctors have good success in treating early-stage lung cancer, so quick detection is key to a good prognosis. Screening is recommended for smokers, but very few people are aware or follow through ...
Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after chemoradiation. [33] Cosibelimab (Unloxcyt) by Checkpoint Therapeutics is a PD-L1 inhibitor developed by Dana Farber, and was approved in the United States in December 2024 for cutaneous squamous cell carcinoma. [34]
Approximately 98% of lung cancers are carcinoma, a term describing malignancies derived from transformed cells exhibiting characteristics of epithelium. About 2% of all lung cancers are non-carcinoma (mainly sarcoma, tumors of hematopoietic origin, or germ cell tumors. [5] These forms of lung cancer are usually treated differently from carcinomas.